Seeking Alpha EN

Cartesian Therapeutics GAAP EPS of -$5.02 misses by $2.67, revenue of $2.79M beats by $0.82M

Mar 09, 2026 &03050909202631; 11:05 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -65/100

High impact Immediate effect (hours)

WHAT THIS MEANS

Cartesian Therapeutics reported a significant GAAP EPS miss of -$5.02 versus expectations of -$2.35, indicating substantial losses, though revenue of $2.79M exceeded estimates by $0.82M. The company's inability to control operating expenses relative to revenue generation presents a concerning profitability outlook despite revenue beat.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

CAYM

CAYMStock

Expected to decline

Significant EPS miss of $2.67 indicates operational inefficiency and cash burn concerns despite revenue beat; biotech companies with large losses and limited revenue face investor skepticism

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Avoid or reduce positions in CAYM; the significant EPS miss despite revenue beat suggests deteriorating unit economics and unsustainable cash burn. Monitor cash runway and upcoming clinical/commercial milestones before reconsidering entry.

KEY SIGNALS

Large EPS miss despite revenue beat signals operational challengesNegative EPS of -$5.02 indicates substantial net lossesRevenue growth insufficient to offset operating expensesCash burn rate appears accelerating relative to revenue generationBiotech company in early commercialization phase with profitability concerns

SECTORS INVOLVED

HealthcareBiotechnologyPharmaceuticals

Analysis generated on Mar 09, 2026 at 13:47 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Cartesian Therapeutics GAAP EPS of -$5.02 misses by $2.67, revenue of $2.79M beats by $0.82M

RELATED INTELLIGENCE